From $4 Billion to Small Bets: Vijay Pande and the New Paradigm of AI Investment in Biotech

Vijay Pande's change of course is anything but ordinary in the world of venture capital. After leading a roughly $4 billion biotech practice at Andreessen Horowitz (a16z), he decided last year to start from scratch, launching VZVC—a significantly smaller investment vehicle focused exclusively on startups built natively around artificial intelligence.

Why fewer bets are worth more

According to TechCrunch, Pande laid out the philosophy behind this shift in clear terms: "We're not doing 30 bets a year," he said, emphasizing that his current strategy relies on a smaller number of far more carefully selected investments. This approach stands in sharp contrast to the classic venture capital model, where broad portfolio diversification is treated as a form of protection against risk.

In the investor's view, concentrating resources and attention on a small number of companies allows for much deeper involvement in product development—particularly in a field as complex as AI-driven biotechnology.

Biology's shift from a science of discovery to a science of engineering

One of Pande's central arguments is that biology is undergoing a fundamental transformation, moving away from a discipline built on chance discovery and toward one governed by predictable, engineering-like principles. This shift is being driven directly by advances in artificial intelligence, which now make it possible to model and anticipate biological behavior at an unprecedented level.

Even so, the investor acknowledges that the industry still faces major obstacles—chief among them the extremely high cost of clinical trials, which remains a significant bottleneck even as drug-discovery technology advances rapidly.

Open data versus closed data

Perhaps the most counterintuitive of Pande's positions, given his background as a corporate investor, is his belief that open, shared datasets—not proprietary, siloed ones—will be the real engine driving AI's transformation of medicine. This view runs against the grain of many biotech companies, which tend to guard their data closely as a competitive advantage.

For the business sector, Pande's move signals a broader reshaping of how venture capital approaches investment in AI applied to science: fewer deals, deeper engagement, and a bet on open collaboration over the traditional corporate instinct toward secrecy.